Gumlink Positioned for Global Growth

VEJLE, DenmarkGumlink announced it is expanding the global focus of its patented nutraceutical gum technology. The company has invested approximately 10 million in technology research and increased capacity, which it said has improved product quality and the ability to include various nutritional active ingredients. Gumlink has completed bioavailability studies showing its chewing gum is equally efficient to pills and capsules in delivery various nutraceutical ingredients. Concepts have been developed within the oral health, immune health, weight management, joint health, heart health and energy segments; omega-3 combinations are also under investigation.

In additional news, Gumlink has been exploring new types of gum base polymers that stick less to dentures, and that are more degradable than existing chewing gums. The company has also initiated a product development program fueled by its sister company Fertin Pharma to unveil new product concepts each quarter during 2011.

Soren Birn, CEO of Gumlink, said: As the consumer choices involved with health care products are broader and more generic than ever before, we are confident that our unique nutritional delivery system will pave the way for a fast and consumer friendly adoption as was the case with nicotine chewing gums in the 90s."